Pq Bypass

PQ Bypass Unveils New Data From DETOUR I at VIVA 17

Seroba’s investee company, PQ Bypass, today announced data from a subset analysis of the DETOUR I clinical trial during a late-breaking clinical trial session at Vascular InterVentional Advances (VIVA 17), which is taking place September 11-14 in Las Vegas.

The study evaluated the safety and effectiveness of the DETOUR System for treating long-segment (>25cm) blockages in the femoropopliteal artery via a novel, fully percutaneous bypass approach, known as the DETOUR procedure.
The presentation by Sean Lyden, M.D., chairman of the vascular surgery department at Cleveland Clinic, was entitled: Safety and Efficacy of a Novel Percutaneous Bypass Procedure for Long-Segment Femoropopliteal Disease: A Sub-Analysis (>25cm) from the DETOUR I Trial.

Percutaneous femoropopliteal bypass (the DETOUR procedure) is a newly developed procedure that utilizes the proprietary DETOUR System – TORUS Stent Graft, DETOUR Crossing Device and DETOUR Snare – to enable a fully percutaneous bypass of long-segment blockages in the femoropopliteal artery.

The DETOUR procedure creates a pathway around a lesion by placing stent grafts that cross from the femoral artery into the femoral vein and back into the artery.  The new path re-directs oxygen-rich blood around the blockage and restores blood flow to the lower leg and foot of the patient. The restoration of blood flow helps to reduce pain and improve patient mobility, all while limiting the progression of PAD.

About PQ Bypass

PQ Bypass, Inc. is a Silicon Valley-based medical device company working to transform the treatment of long-segment peripheral artery disease with minimally invasive endovascular solutions.

PQ Bypass is operated by recognized leaders in the medical device industry including veterans from Medtronic, Abbott, Johnson & Johnson, and Stryker. The underlying technology and technique used in the percutaneous DETOUR procedure were co-developed by two world-renowned cardiologists and innovators, Dr. James Joye and Dr. Richard Heuser, who are recognized experts in peripheral artery disease.

Note: The DETOUR System is not available for sale in the U.S.

For more information, please visit www.pqbypass.com or contact Vicky La Touche-Price at Seroba Life Sciences on +353 (0)1 6334028.

Recent Articles

Home V2

Seroba Invests in Storm Therapeutics

20 May 2019.  STORM Therapeutics (“STORM”), the drug discovery company tackling disease through modulating RNA modifying enzymes, has announced that […]

Read More
Quanta SC+

Quanta SC+ confirmed as safe and easy to use

Alcester, Warwickshire, UK, 15 April 2019.  Seroba’s portfolio company, Quanta Dialysis Technologies Ltd (“Quanta” or the “Company”), a pioneering medical […]

Read More
Fusion

Fusion Raises $105m in Series B Financing

April 2nd 2019. Hamilton, Canada and Dublin, Ireland.  Seroba’s portfolio company, Fusion Pharmaceuticals, a clinical-stage biopharmaceutical company developing targeted alpha-particle […]

Read More
Jen Moderator Session On Investment Cycles

VCs with €6Bn in Funds to Invest Visit Dublin

The sixth annual MedTech Strategist Innovation Summit Dublin will take place this April in the Shelbourne Hotel. Dozens of Venture […]

Read More
T: 353 (0)1 633 4028

18 Herbert Street
Dublin 2
D02 FK19
Ireland

Scroll to Top